Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.8300 (-7.58%) ($6.8200 - $7.4500) on Fri. Mar. 22, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.48% (three month average) | RSI | 51 | Latest Price | $6.8300(-7.58%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 6.7% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) IWO(57%) ARKK(56%) | Factors Impacting TGTX price | TGTX will decline at least -2.74% in a week (0% probabilities). VXX(-16%) UUP(-11%) TLT(-9%) VIXM(-8%) IFRA(-5%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.74% (StdDev 5.48%) | Hourly BBV | 0 () | Intraday Trend | -7.3% | | | |
|
5 Day Moving Average | $7.3(-6.44%) | 10 Day Moving Average | $7.09(-3.67%) | 20 Day Moving Average | $6.63(3.02%) | To recent high | -8.3% | To recent low | 31.6% | Market Cap | $865m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |